MOLN Molecular Partners AG

2.563USD2.160 CHF · SWX-3.57%Mkt Cap: 98.26M USDP/E: —

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP03…

Institutional holders4 on file

Key Statistics

Company
Market Cap98.26M USD
Enterprise Value33.29M USD
Revenue (TTM)—
Gross Profit-46.44M USD
Net Income (TTM)-73.16M USD
Revenue/Share—
Last Price2.563 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees134
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0256379097
Valuation
P/E (Trailing)—
P/E (Forward)1.19
PEG—
EV/EBITDA-0.55
EV/Revenue—
P/S—
P/B1.63
EPS (TTM)-1.59 USD
EPS (Forward)2.15 USD
52W Range
2.3738% of range4.699
52W High4.699 USD
52W Low2.373 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-76.74%
ROA-60.38%
ROIC—
ROCE-60.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-60.82M USD
CapEx (TTM)847.25K USD
FCF Margin—
FCF Yield-33.71%
Net Debt-64.97M USD
Net Debt/EBITDA1.07
Net Debt/FCF—
Balance Sheet
Debt/Equity0.05
Current Ratio6.46
Quick Ratio6.28
Book Value/Sh1.57 USD
Cash/Share1.78 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.68 USD
Upside (mean)+316.7%
Target Range3.560 USD – 17.80 USD
3.560+316.7% to mean17.80
# Analysts2
Ownership
Shares Out.38.34M
Float20.74M
Insiders8.47%
Institutions43.77%
Technical
SMA 503.605 (-28.9%)
SMA 2003.866 (-33.7%)
Beta0.61
S&P 52W Chg12.00%
Avg Vol (30d)32.33K
Avg Vol (10d)48.02K
Technical Indicators
RSI (14)20.4
MACD-0.2332
MACD Signal-0.1991
MACD Hist.-0.0341
BB Upper3.894 USD
BB Middle3.149 USD
BB Lower2.405 USD
BB Width47.26%
ATR (14)0.1804 USD
Vol Ratio (20d)0.58x

About Molecular Partners (SWX: MOLN)

›

Molecular Partners (SWX: MOLN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 134 employees.

The shares were at 2.160 CHF on 19 November 2026, down 30.3% over 52 weeks. Its 52-week range is 2.000 CHF to 3.960 CHF: the price is 45.5% below the high and 8.0% above the low.

Its market capitalisation is 82.80M CHF.

Molecular Partners reports return on equity of -76.7% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 54.75M CHF. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.